{"created":"2024-06-03T11:11:39.545411+00:00","id":2000100,"links":{},"metadata":{"_buckets":{"deposit":"d6179a52-fd4f-4459-abf0-487ffa626672"},"_deposit":{"created_by":18,"id":"2000100","owner":"18","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"2000100"},"status":"published"},"_oai":{"id":"oai:osaka-dent.repo.nii.ac.jp:02000100","sets":["1686642104765:1:63:65"]},"author_link":[],"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2024-03-01"}]},"item_10006_degree_grantor_9":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"大阪歯科大学"},{"subitem_degreegrantor_language":"en","subitem_degreegrantor_name":"Osaka Dental University"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"34408","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（歯学）","subitem_degreename_language":"ja"}]},"item_10006_description_7":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"This study aimed to examine the medical costs associated with oral and pharyngeal cancers using a large administrative claims database in Japan. Economic evaluation is crucial for maintaining universal health coverage in Japan. This study used the administrative claims database of 21,736 patients diagnosed with oral or pharyngeal cancer between April 2005 and December 2020. We calculated propensity scores based on age, sex, cancer site, lymph node metastasis, and first treatment. Using propensity score matching, we selected 195 participants from each group and compared treatment cost with and without cetuximab. The average monthly medical cost was 525,551 and 285,239 yen for the cetuximab administration and non-administration groups, respectively. When compared by sex, age, and cancer site, costs remained significantly higher for oral and pharyngeal than for salivary gland cancers. Among the conditions during treatment, 11.8% of patients experienced hypomagnesemia due to cetuximab administration, while 7.7% exhibited common acne. Patients in the cetuximab administration group were more commonly diagnosed with cancer-related pain, oral mucositis, and difficulties with oral intake. The cost for patients with oral cancer is related to patient characteristics and treatment patterns. Acknowledging the high medical expenses and need for careful attention to complications that may occur is essential.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10006_dissertation_number_12":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第988号"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"作成者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"北山, 貴也","creatorNameLang":"ja"},{"creatorName":"キタヤマ, タカヤ","creatorNameLang":"ja-Kana"},{"creatorName":"Kitayama, Takaya","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2024-06-01"}],"filename":"kou_988_ab.pdf","filesize":[{"value":"279 KB"}],"format":"application/pdf","url":{"label":"本文内容要旨・審査結果要旨","objectType":"abstract","url":"https://osaka-dent.repo.nii.ac.jp/record/2000100/files/kou_988_ab.pdf"},"version_id":"cc04bdfc-1bdf-466e-8176-37b923b80d5e"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Oral cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cetuximab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Administrative","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"claims database","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Cost analysis among oral cancer patients with and without  cetuximab using administrative claims database in Japan","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Cost analysis among oral cancer patients with and without  cetuximab using administrative claims database in Japan","subitem_title_language":"en"},{"subitem_title":"レセプトデータを用いた口腔・咽頭がん患者に対するセツキシマブの治療実態に関する疫学研究","subitem_title_language":"ja"}]},"item_type_id":"10006","owner":"18","path":["65"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2024-06-01"},"publish_date":"2024-06-01","publish_status":"0","recid":"2000100","relation_version_is_last":true,"title":["Cost analysis among oral cancer patients with and without  cetuximab using administrative claims database in Japan"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2024-06-03T11:15:35.721962+00:00"}